Adjuvant Colon Cancer w/ ELOXatin®/5 FU Based Regimen: ACCELOX

King Faisal Specialist Hospital & Research Center

Status: Completed

Conditions: Colon Cancer

Treatments: Other: Registry

Study type: Observational

Funder types: Other

Identifiers

NCT01310972

RAC# 2071-027 (Other Identifier)

Details and patient eligibility

About

Adjuvant Colon Cancer With ELOXatin®/5 FU Based Regimen: ACCELOX

Full description

It's a study of adjuvant colon carcinoma using ELOXatin/5-FU based chemotherapeutic regimen called ACCELOX as a definitive curative therapy.

Enrollment: 6 patients

Sex: All

Ages: 14 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with Adjuvant Colon Cancer

Exclusion criteria

• Patients with diagnosis other than Colon Cancer.